BiotechTube
Home/Ryvu Therapeutics/Marcin Król
MK

Marcin Król

Chief Technology Officer

Ryvu Therapeutics

Therapeutic Areas

OncologyHematology

Ryvu Therapeutics Pipeline

DrugIndicationPhase
RVU120 (XPO1 inhibitor)Relapsed/Refractory AML, HR-MDSPhase I/II
RVU120 (STING agonist)Advanced Solid TumorsPhase I
BTX-1188 (HPK1 inhibitor)Advanced Solid TumorsPhase I

Leadership Team at Ryvu Therapeutics

PP
Pawel Przewiezlikowski
Chief Executive Officer
KB
Krzysztof Brzózka
Chief Scientific Officer
HN
Hendrik Nogai
Chief Medical Officer
View full Ryvu Therapeutics profile